| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/11/2002 | WO2002028867A2 Ethers of 7-desmethylrapamycin for use in immunosuppression |
| 04/11/2002 | WO2002028866A2 Hydroxyesters of 7-desmethylrapamycin |
| 04/11/2002 | WO2002028865A2 Condensed pyridoindole derivatives |
| 04/11/2002 | WO2002028864A1 New process for the production of oxabispidines |
| 04/11/2002 | WO2002028863A1 New oxabispidine compound useful in the treatment of cardiac arrhythmias |
| 04/11/2002 | WO2002028862A2 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 04/11/2002 | WO2002028860A2 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| 04/11/2002 | WO2002028859A2 Condensed pyridoindole derivatives |
| 04/11/2002 | WO2002028858A2 Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
| 04/11/2002 | WO2002028856A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/11/2002 | WO2002028855A2 Amorphous form of cell cycle inhibitor |
| 04/11/2002 | WO2002028851A1 7-carboxy-flavone derivatives, preparation method and therapeutic use |
| 04/11/2002 | WO2002028850A1 Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells |
| 04/11/2002 | WO2002028847A1 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors |
| 04/11/2002 | WO2002028842A2 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist |
| 04/11/2002 | WO2002028839A1 Benzimidazole and indole derivatives as crf receptor modulators |
| 04/11/2002 | WO2002028837A1 Metabotropic glutamate receptor antagonists |
| 04/11/2002 | WO2002028836A1 Novel crystalline forms of a factor xa inhibitor |
| 04/11/2002 | WO2002028835A1 Benzamide compounds as apo b secretion inhibitors |
| 04/11/2002 | WO2002028832A2 Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
| 04/11/2002 | WO2002028831A1 Inhibitors of prenyl-protein transferase |
| 04/11/2002 | WO2002028830A1 Novel phenylalanine derivatives |
| 04/11/2002 | WO2002028828A1 Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| 04/11/2002 | WO2002028825A2 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors |
| 04/11/2002 | WO2002028824A1 Citrullimycines, a process for their production and their use as pharmaceuticals |
| 04/11/2002 | WO2002028823A1 Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use |
| 04/11/2002 | WO2002028820A1 Nitroso diphenylamine derivatives |
| 04/11/2002 | WO2002028819A1 Naphthylsalicylanilides as antimicrobial and antiinflammatory agents |
| 04/11/2002 | WO2002028817A1 Substituted 1-aminobutan-3-ol derivatives |
| 04/11/2002 | WO2002028816A1 Substituted 5-amino-1-pentene-3-ol derivatives |
| 04/11/2002 | WO2002028815A1 Pharmaceutical compounds |
| 04/11/2002 | WO2002028814A2 Nmda receptor channel blocker with neuroprotective activity |
| 04/11/2002 | WO2002028810A2 Retinoids for the treatment of emphysema |
| 04/11/2002 | WO2002028440A1 Methods and compositions for modulating t cell activation and uses thereof |
| 04/11/2002 | WO2002028435A1 Pharmaceutical vehicle |
| 04/11/2002 | WO2002028434A2 Use of a ppar delta activator for treating inflammatory conditions |
| 04/11/2002 | WO2002028433A2 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 04/11/2002 | WO2002028432A2 Stem cell-based methods for preventing and treating tumor |
| 04/11/2002 | WO2002028431A1 Remedies for hepatic diseases containing calcium channel antagonist as the active ingredient |
| 04/11/2002 | WO2002028430A2 Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| 04/11/2002 | WO2002028424A2 Kyberdrug as autovaccines with immune-regulating effects |
| 04/11/2002 | WO2002028421A1 Methods of inhibition of stenosis and/or sclerosis of the aortic valve |
| 04/11/2002 | WO2002028418A1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 04/11/2002 | WO2002028414A1 Compositions and methods for wt1 specific immunotherapy |
| 04/11/2002 | WO2002028409A2 Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| 04/11/2002 | WO2002028406A2 Induction of blood vessel formation by polynucleotides encoding sphingosine kinases |
| 04/11/2002 | WO2002028404A1 Eye drops |
| 04/11/2002 | WO2002028403A1 Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus |
| 04/11/2002 | WO2002028401A1 Fluoride as a chemoprotective and chemotherapeutic agent for cancer in mammals |
| 04/11/2002 | WO2002028400A1 A therapeutic formulation containing glucosamine, methylsulfonymethane and eventually ascorbic acid and manganese |
| 04/11/2002 | WO2002028399A1 Apoptosis inducers, caspase cascade activators and anticancer agents |
| 04/11/2002 | WO2002028398A1 Compositions for treating diabetes |
| 04/11/2002 | WO2002028397A1 Diabetes remedies |
| 04/11/2002 | WO2002028396A1 Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid |
| 04/11/2002 | WO2002028395A1 Phosphoric acid salt of an integrin receptor antagonist |
| 04/11/2002 | WO2002028394A1 Use of medicaments |
| 04/11/2002 | WO2002028393A1 Use of neuropeptide-y antagonists in treatment of alcoholism |
| 04/11/2002 | WO2002028392A1 Remedies for brain circulatory disturbances |
| 04/11/2002 | WO2002028391A1 Blocking inflammation by inhibiting sialylation |
| 04/11/2002 | WO2002028390A1 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 04/11/2002 | WO2002028389A1 Antitumor therapy comprising distamycin derivatives |
| 04/11/2002 | WO2002028388A2 Use of mek1 inhibitors as protective agents against damage due to ischemia |
| 04/11/2002 | WO2002028387A1 Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| 04/11/2002 | WO2002028386A1 Method for preparing microspheres containing a water-soluble substance |
| 04/11/2002 | WO2002028385A1 Compositions and methods for designing and using compositions which inhibit activated helper t cells |
| 04/11/2002 | WO2002028384A1 Chloramines as antiviral agents |
| 04/11/2002 | WO2002028383A1 Delivery system for multi-pharmaceutical active materials at various release rates |
| 04/11/2002 | WO2002028382A1 Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals |
| 04/11/2002 | WO2002028381A2 Methods of inducing cancer cell death and tumor regression |
| 04/11/2002 | WO2002028380A2 Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same |
| 04/11/2002 | WO2002028379A2 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 04/11/2002 | WO2002028378A1 Combination particles for the treatment of asthma |
| 04/11/2002 | WO2002028377A1 Ihnalation particles incorporating a combination of two or more active ingredients |
| 04/11/2002 | WO2002028376A2 Chrono delivery formulations and method of use thereof |
| 04/11/2002 | WO2002028373A1 New pharmaceutical compositions containing epinastine and pseudoephedrine |
| 04/11/2002 | WO2002028368A1 New combination for the treatment of asthma |
| 04/11/2002 | WO2002028366A2 Devices and methods for management of inflammation |
| 04/11/2002 | WO2002028364A2 Stabilization of solid thyroid drug formulations |
| 04/11/2002 | WO2002028363A1 Eye instillation with decongestant effect |
| 04/11/2002 | WO2002028361A2 Compositions for cleansing skin and treating acne |
| 04/11/2002 | WO2002028355A2 Methods and compositions for enhancing angiogenesis |
| 04/11/2002 | WO2002028351A2 Recombinant mucin binding proteins from steptococcus pneumoniae |
| 04/11/2002 | WO2002028349A2 Method of treating cancer using dithiocarbamate derivatives |
| 04/11/2002 | WO2002028348A2 Compositions and methods for treatment of cystic fibrosis |
| 04/11/2002 | WO2002028347A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 04/11/2002 | WO2002028346A2 Association of the cb1 receptor antagonist and sibutramin, for treating obesity |
| 04/11/2002 | WO2002028270A2 The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor |
| 04/11/2002 | WO2002028181A1 Sustained release pharmaceutical compositions containing metformin and method of its production |
| 04/11/2002 | WO2002028180A2 Antimicrobial compositions formulated for use in cold temperature conditions and methods of use thereof |
| 04/11/2002 | WO2002012288A3 Vaccination against host cell-associated herpesviruses |
| 04/11/2002 | WO2002007766A8 Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia |
| 04/11/2002 | WO2002007715A3 A method for treating celiac disease |
| 04/11/2002 | WO2002007533A3 Nutritional composition |
| 04/11/2002 | WO2002007514A3 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| 04/11/2002 | WO2002004531A3 Process for preparing benzoxazin-4-one polymer conjugates |
| 04/11/2002 | WO2002000725A3 G-protein coupled receptor org10 |
| 04/11/2002 | WO2001094279A3 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls |
| 04/11/2002 | WO2001092581A8 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 04/11/2002 | WO2001090070A3 Caspase inhibitors and uses thereof |
| 04/11/2002 | WO2001090069B1 Novel calcium receptor active molecules and method for preparing same |